lung
normal
dual
blood
suppli
consist
larg
pulmonari
arteri
provid
desatur
blood
low
pressur
alveolar
ga
exchang
smaller
bronchial
arteri
provid
oxygen
blood
system
pressur
nutrit
oxygen
bronchi
lung
tissu
solid
organ
transplant
undergo
primari
system
ie
bronchial
arteri
revascular
time
surgeri
lung
transplant
reli
deoxygen
pulmonari
arteri
circul
especi
vulner
effect
injuri
ischemia
hypothes
absenc
bronchial
system
lung
allograft
increas
suscept
microvascular
injuri
chronic
airway
ischemia
may
implic
genesi
chronic
reject
complic
similarli
nativ
lymphat
neural
suppli
lung
allograft
disrupt
time
transplant
impact
disrupt
lung
transplant
outcom
remain
unclear
though
possibl
chang
lead
higher
suscept
develop
pulmonari
edema
infect
wors
airway
clearanc
ineffect
cough
lastli
lung
allograft
higher
exposur
immunogen
compound
compar
organ
ventil
ongo
exposur
variou
inhal
injuri
agent
may
also
predispos
lung
allograft
develop
chronic
reject
vast
array
complic
lung
transplant
broadli
complic
divid
noninfecti
infecti
complic
summar
tabl
complic
aris
differ
time
postop
period
understand
time
variou
complic
postlung
transplant
lead
earli
recognit
manag
complic
epithelium
alveolar
macrophag
interact
cell
lead
releas
cytokin
reactiv
oxygen
intermedi
proteolyt
enzym
lead
graft
dysfunct
sever
pgd
fall
along
spectrum
rang
mild
dysfunct
sever
lung
injuri
pgd
affect
transplant
patient
mortal
high
furthermor
sever
pgd
lung
transplant
associ
develop
subsequ
chronic
reject
graft
dysfunct
manag
pgd
larg
support
includ
lungprotect
ventil
strategi
low
tidal
volum
high
posit
endexpiratori
pressur
judici
fluid
manag
inhal
nitric
oxid
inhal
pulmonari
vasodil
improv
oxygen
extracorpor
life
support
ecl
sever
case
retransplant
option
highli
select
case
gener
recommend
due
suboptim
outcom
lung
transplant
recipi
increas
risk
vte
risk
factor
includ
major
surgeri
statu
hypercoagul
state
high
dose
corticosteroid
immobl
indwel
vascular
access
report
incid
pulmonari
embol
pe
deep
venou
thrombosi
dvt
postlung
transplant
approxim
respect
pulmonari
embol
set
limit
pulmonari
reserv
due
pgd
postop
atelectasi
singlelung
transplant
catastroph
consequ
thu
underscor
need
earli
appropri
vte
prophylaxi
lung
transplant
diagnosi
made
comput
tomographi
ct
pulmonari
angiographi
ventilationperfus
scan
document
dvt
doppler
ultrasonographi
treatment
vte
gener
although
risk
postop
bleed
need
weigh
risk
pe
choic
anticoagul
base
kidney
function
periprocedur
revers
anticoagul
effect
drug
interact
unfraction
heparin
lowmolecularweight
heparin
andor
warfarin
far
common
agent
use
case
ongo
bleed
high
risk
bleed
inferior
vena
cava
filter
use
tempor
measur
inadvert
injuri
variou
intrathorac
nerv
lung
transplant
wellrecogn
common
complic
commonli
affect
structur
phrenic
vagu
nerv
report
rate
phrenic
nerv
injuri
rang
lung
transplant
case
rate
high
combin
heartlung
transplant
diaphragmat
dysfunct
consequ
phrenic
nerv
injuri
present
clinic
dyspnea
hypoventil
hypercapnia
hypoxemia
difficult
wean
ventil
diaphragmat
paralysi
lead
increas
length
stay
ventil
depend
diagnosi
confirm
document
paradox
movement
affect
diaphragm
quiet
deep
breath
use
fluoroscopi
ultrasound
visual
vagal
nerv
injuri
postlung
transplant
lead
gastroparesi
associ
risk
gastroesophag
reflux
gerd
aspir
event
turn
place
lung
allograft
risk
recurr
infect
bronchiectasi
possibl
chronic
allograft
dysfunct
common
symptom
gastroparesi
includ
earli
satieti
decreas
appetit
abdomin
pain
bloat
diagnosi
usual
made
nuclear
medicin
gastric
empti
studi
potenti
manag
strategi
includ
minim
transit
delay
medic
eg
opioid
use
promotil
agent
placement
postpylor
feed
tube
botulinum
toxin
inject
pyloru
surgic
fundopl
conjunct
pyloroplasti
pleural
complic
earli
postlung
transplant
period
includ
pleural
effus
hemothorax
pneumothorax
empyema
chylothorax
interpleur
commun
complic
usual
aris
result
pleural
disrupt
surgeri
though
reject
immunosuppress
regimen
may
also
play
role
risk
factor
develop
pleural
complic
includ
previou
thorac
surgeri
pleural
adhes
donorrecipi
size
mismatch
pleural
effus
extrem
common
earli
postlung
transplant
period
report
incid
seri
patient
chest
tube
place
immedi
postoper
allow
lung
reexpans
pleural
air
fluid
drainag
increas
amount
pleural
fluid
postlung
transplant
relat
capillari
leak
due
allograft
ischemia
reperfus
fluid
overload
bleed
surgic
interrupt
allograft
lymphat
time
explant
late
pleural
effus
consequ
infect
acut
reject
trap
lung
physiolog
pleural
fibrosi
malign
gener
pleural
effus
need
evalu
rule
complic
effus
hemothorax
empyema
chylothorax
entiti
associ
neg
patient
outcom
treat
rang
medic
surgic
procedur
depend
condit
sever
exampl
chylothorax
might
necessit
mechan
interrupt
thorac
duct
hemothorax
may
need
thoracotomi
control
bleed
pneumothorax
common
lung
transplant
result
donorrecipi
size
mismatch
bronchopleur
fistula
occur
secondari
oper
injuri
bronchial
anastomos
dehisc
consequ
transbronchi
biopsi
perform
cours
allograft
evalu
small
stabl
pneumothorax
lung
transplant
manag
watch
wait
though
larger
symptomat
pneumothorax
may
requir
chest
tube
drainag
inadequ
drain
hemodynam
signific
pneumothorax
medic
emerg
necessit
urgent
drainag
patient
undergon
sequenti
bilater
lung
transplant
bslt
heartlung
transplant
hlt
interpleur
commun
due
surgic
sever
pleural
recess
separ
left
right
pleural
space
develop
entail
pleural
issu
patient
must
manag
aggress
pneumothorax
bilater
life
threaten
empyema
spread
quickli
vascular
anastomot
complic
aris
either
earli
late
posttranspl
cours
sever
advers
consequ
pulmonari
arteri
stenosi
secondari
mechan
kink
disrupt
narrow
anastomosi
sometim
due
particular
donor
anatomi
due
thrombosi
clinic
pictur
usual
consist
pulmonari
hypertens
right
ventricular
failur
diagnosi
made
pulmonari
angiographi
manag
intervent
balloon
dilat
stent
deploy
occasion
patient
may
requir
surgeri
definit
manag
stenosi
pulmonari
vein
occlus
postlung
transplant
rare
seriou
complic
commonest
caus
pulmonari
vein
occlus
develop
thrombosi
anastomot
junction
pulmonari
vein
left
atrium
though
inadvert
narrow
ligat
pulmonari
vein
also
report
potenti
clinic
consequ
includ
hypox
respiratori
failur
pulmonari
edema
cardioembol
event
entiti
includ
differenti
diagnosi
patient
acut
pulmonari
edema
postlung
transplant
diagnosi
usual
made
transesophag
echocardiographi
ct
angiographi
airway
complic
lung
transplant
classifi
time
occurr
earli
anastomot
complic
usual
within
month
transplant
includ
infect
dehisc
necrosi
anastomot
site
later
complic
includ
bronchopleur
bronchovascular
bronchomediastin
fistula
excess
granul
tissu
bronchomalacia
airway
stenosi
airway
anastomot
complic
seem
associ
decreas
surviv
howev
neg
impact
qualiti
life
significantli
increas
healthcar
resourc
util
risk
factor
airway
anastomot
complic
includ
colon
burkholderia
cepacia
aspergillu
fumigatu
pgd
acut
reject
prolong
mechan
ventil
sirolimu
use
prior
anastomot
heal
bronchial
necrosi
dehisc
occur
week
transplant
present
dyspnea
difficulti
wean
ventil
persist
air
leak
water
seal
pneumomediastinum
subcutan
emphysema
infect
symptom
rang
mild
sever
depend
sever
manag
rang
observ
antibiot
minim
invas
surgic
repair
bronchial
stenosi
narrow
airway
lumen
usual
site
anastomosi
patient
present
wheez
cough
postobstruct
pneumonia
declin
pulmonari
function
test
pft
stridor
bronchial
narrow
also
present
distal
anastomosi
caus
lobar
lobe
collaps
syndrom
occur
month
posttranspl
present
late
month
treatment
option
includ
close
monitor
bronchial
dilat
without
stent
placement
retransplant
allograft
reject
major
caus
morbid
mortal
postlung
transplant
least
third
patient
report
acut
reject
first
year
transplant
acut
reject
seldom
lead
mortal
main
risk
factor
develop
chronic
reject
chronic
reject
lung
allograft
major
hurdl
longterm
surviv
transplant
despit
use
potent
novel
immunosuppress
regimen
incid
chronic
reject
longterm
surviv
posttranspl
remain
essenti
unchang
last
two
decad
acut
cellular
reject
acr
common
kind
acut
lung
transplant
reject
mediat
lymphocyt
symptom
sign
acr
includ
dyspnea
cough
fever
hypoxia
highgrad
reject
may
associ
respiratori
failur
mild
acr
asymptomat
frequent
detect
surveil
pulmonari
function
test
andor
transbronchi
biopsi
current
imag
modal
diagnost
may
reveal
use
find
infiltr
groundglass
opac
flexibl
bronchoscopi
transbronchi
biopsi
gold
standard
diagnosi
histolog
acr
character
presenc
perivascular
andor
peribronchiolar
grade
b
lymphocyt
absenc
infecti
etiolog
risk
factor
acr
includ
number
hla
mismatch
donor
recipi
although
unclear
specif
hla
impact
report
risk
factor
age
older
patient
reject
immunosuppress
regimen
use
tacrolimu
regimen
reject
less
genet
factor
product
document
gerd
acr
also
document
follow
infect
certain
virus
rhinoviru
parainfluenza
viru
influenza
viru
human
metapneumoviru
coronaviru
respiratori
syncyti
viru
treatment
acr
uniform
highqual
random
control
trial
lack
wide
agreement
sever
case
acr
must
treat
variabl
among
transplant
center
whether
treat
milder
case
mainstay
therapi
highdos
corticosteroid
case
refractori
recurr
usual
immunosuppress
regimen
get
intensifi
alter
medic
antithymocyt
globulin
atg
antiinterleukin
antagonist
alemtuzumab
monoclon
antibodi
among
other
use
antibodymedi
reject
amr
believ
mediat
donorspecif
antibodi
dsa
human
leukocyt
antigen
hla
donor
antigen
antibodi
may
present
recipi
prior
transplant
although
appear
develop
transplant
amr
describ
combin
follow
donorspecif
antihla
antibodi
evid
complement
deposit
allograft
biopsi
histolog
tissu
injuri
clinic
allograft
dysfunct
aforement
antibodi
bind
receptor
graft
capabl
bind
complement
specif
trigger
complementmedi
cell
destruct
inflamm
develop
de
novo
antihla
antibodi
associ
poor
prognosi
mainstay
amr
manag
involv
deplet
andor
neutral
antihla
antibodi
plasma
exchang
intraven
immunoglobulin
ivig
follow
rituximab
infus
rituximab
chimer
antibodi
target
bcell
function
decreas
product
antibodi
case
refractori
amr
newer
agent
bortezomib
antiproteasom
anticompl
antibodi
eculizumab
tri
limit
success
success
clearanc
antihla
antibodi
associ
decreas
risk
develop
chronic
reject
follow
amr
term
chronic
lung
allograft
dysfunct
clad
encompass
patholog
lead
chronic
dysfunct
lung
allograft
clad
predominantli
consequ
chronic
reject
major
hurdl
longterm
surviv
two
major
phenotyp
clad
includ
bronchiol
obliteran
syndrom
bo
ii
restrict
allograft
syndrom
ra
bo
predomin
form
clad
number
one
caus
death
year
transplant
report
occur
lung
transplant
recipi
year
posttranspl
major
caus
morbid
neg
impact
qualiti
life
increas
cost
bo
defin
sustain
week
declin
forc
expiratori
volum
first
second
expir
provid
altern
caus
pulmonari
dysfunct
exclud
tissu
level
hallmark
bo
oblit
bronchiol
ob
inflammatoryfibrot
process
affect
small
noncartilagin
airway
membran
respiratori
bronchiol
character
subepitheli
fibrosi
caus
partial
complet
lumin
occlus
risk
factor
includ
prior
episod
acut
reject
cytomegaloviru
infect
cmv
communityacquir
respiratori
virus
carv
infect
histori
pgd
isol
aspergillu
fumigatu
pseudomona
aeruginosa
presenc
gerd
immunemedi
factor
diagnosi
made
condit
without
histopatholog
bo
definit
histopatholog
bo
transbronchi
biopsi
insensit
method
detect
bo
clinic
use
bo
favor
method
diagnosi
monitor
treatment
bo
disappoint
term
outcom
often
success
measur
slow
declin
stabil
beyond
augment
immunosuppress
azithromycin
extracorpor
photopheresi
montelukast
methotrex
aerosol
cyclosporin
alemtuzumab
total
lymphoid
irradi
use
limit
success
ra
recent
describ
occur
less
third
patient
clad
patient
present
predomin
restrict
surviv
wors
compar
patient
bo
median
surviv
postdiagnosi
month
ct
scan
show
interstiti
opac
groundglass
opac
upper
lobedomin
fibrosi
honeycomb
identifi
risk
factor
develop
ra
lateonset
diffus
alveolar
damag
dad
occur
later
month
lung
transplant
proven
treatment
condit
retransplant
remain
technic
challeng
lung
transplant
associ
immunosuppress
establish
risk
factor
develop
cancer
commonest
malign
postlung
transplant
squamou
cell
cancer
skin
singlelung
transplant
recipi
higher
risk
develop
lung
cancer
nativ
lung
increas
risk
part
relat
increas
risk
cancer
due
underli
diseas
eg
emphysema
idiopath
pulmonari
fibrosi
similarli
transplant
recipi
cystic
fibrosi
remain
elev
risk
develop
gastrointestin
malign
imper
transplant
recipi
adher
ageappropri
health
screen
transplant
addit
lung
transplant
recipi
undergo
skin
cancer
screen
annual
risk
especi
high
viral
infect
associ
malign
lymphoma
kaposi
sarcoma
anogenit
cancer
posttranspl
lymphoprolif
disord
ptld
encompass
array
diseas
involv
clonal
expans
b
lymphocyt
rang
polyclon
benign
disord
aggress
malign
lymphoma
report
incid
nonhodgkin
lymphoma
postlung
transplant
high
personyear
signific
associ
ptld
epsteinbarr
viru
ebv
infect
especi
patient
acquir
infect
novo
transplant
ptld
manag
reduc
intens
immunosuppress
possibl
specif
chemotherapi
sever
refractori
case
hyperammonemia
affect
lung
transplant
popul
rare
potenti
fatal
complic
secondari
system
infect
mycoplasma
homini
ureaplasma
break
urea
energi
sourc
gener
ammonia
wast
product
like
repres
donorderiv
infect
respond
earli
appropri
antibiot
treatment
postop
liver
dysfunct
ureacycl
enzym
defici
also
caus
hyperammonemia
diabet
mellitu
dm
common
lung
transplant
recipi
patient
develop
first
year
posttranspl
year
use
glucocorticoid
calcineurin
inhibitor
obes
advanc
age
signific
risk
factor
develop
dm
develop
dm
lung
transplant
recipi
associ
decreas
surviv
close
judici
glycem
control
indic
patient
popul
patient
undergo
lung
transplant
multipl
risk
factor
develop
acut
kidney
injuri
aki
posttranspl
includ
decreas
renal
perfus
andor
surgeri
drug
toxic
system
infect
aki
affect
mani
patient
approxim
patient
requir
renal
replac
therapi
rrt
postop
renal
failur
necessit
use
rrt
associ
increas
risk
earli
mortal
year
surviv
lung
transplant
recipi
develop
sever
renal
dysfunct
serum
creatinin
mg
dl
percentag
rise
mark
risk
factor
develop
chronic
kidney
diseas
ckd
includ
older
age
dm
hypertens
smoke
histori
use
nephrotox
drug
ckd
also
associ
higher
mortal
lung
transplant
recipi
recipi
lung
transplant
risk
develop
osteopenia
osteoporosi
due
multipl
factor
malnutrit
immobl
chronic
corticosteroid
use
calcineurin
inhibitor
use
eg
tacrolimu
comorbid
strategi
prevent
revers
bone
loss
transplant
need
proactiv
implement
treatment
includ
adequ
supplement
calcium
vitamin
use
bisphosphon
enhanc
physic
activ
minim
contribut
medic
possibl
dyslipidemia
also
common
lung
transplant
recipi
high
may
relat
aforement
metabol
risk
factor
treatment
usual
entail
lifestyl
modif
cholesterol
lower
medic
multipl
cardiac
complic
lung
transplant
short
long
term
atrial
dysrhythmia
frequent
earli
postop
period
like
relat
stress
major
surgeri
catecholamin
surg
medic
side
effect
mechan
stress
relat
vascular
anastomos
report
incid
high
arrhythmia
usual
manag
medic
aim
rate
rhythm
control
hemodynam
signific
andor
refractori
arrhythmia
may
requir
electr
cardiovers
atrial
dysrhythmia
associ
increas
length
hospit
stay
increas
mortal
long
term
lung
transplant
recipi
increas
risk
develop
coronari
arteri
diseas
cad
progress
longterm
surviv
patient
cumul
impact
risk
factor
previous
discuss
chapter
name
dm
dyslipidemia
ckd
hypertens
chronic
corticosteroid
use
immunosuppress
medic
risk
factor
care
manag
decreas
impact
cad
relat
complic
combin
lifestyl
modif
specif
medic
therapi
lung
transplant
recipi
experi
decreas
skelet
muscl
strength
function
includ
respiratori
limb
muscl
like
relat
reduc
activ
postop
decondit
corticosteroidinduc
myopathi
critic
illnessrel
weak
neuropathymyopathi
case
diaphragm
phrenic
nerv
injuri
issu
seem
consist
lung
transplant
recipi
independ
pretranspl
diagnosi
surgeri
type
muscl
weak
decondit
sarcopenia
associ
advers
outcom
decreas
qualiti
life
aggress
rehabilit
standard
import
posttranspl
care
lung
transplant
recipi
increas
risk
acquir
infect
due
immunosuppress
state
constant
environment
pathogen
exposur
decreas
cough
reflex
impair
mucociliari
clearanc
lymphat
disrupt
infecti
complic
respons
quarter
posttranspl
death
pneumonia
signific
bacteri
infect
lung
transplant
recipi
highest
risk
first
day
posttranspl
earli
period
like
caus
hospitalacquir
organ
tend
virul
resist
antibiot
patient
cystic
fibrosi
frequent
colon
multidrugresist
organ
increas
risk
pneumonia
posttranspl
later
stage
communityacquir
organ
becom
preval
moreov
throughout
posttranspl
period
patient
suscept
numer
opportunist
infect
commonli
encount
bacteri
infect
patient
popul
includ
pleural
space
infect
blood
stream
infect
bsi
soft
tissu
infect
bsi
empyema
carri
high
risk
morbid
mortal
pseudomona
aeruginosa
burkholderia
cepacia
staphylococcu
aureu
includ
methicillinresist
gramneg
organ
common
caus
seriou
infect
postlung
transplant
period
organ
high
rate
antibiot
resist
associ
wors
outcom
streptococcu
pneumonia
common
caus
communityacquir
pneumonia
immunosuppress
patient
increas
risk
dissemin
infect
clostridium
difficil
associ
diarrhea
major
complic
hospit
immunosuppress
debilit
patient
associ
increas
hospit
length
stay
mortal
mold
common
fungal
entiti
affect
lung
allograft
aspergillu
spp
common
predilect
respiratori
tract
lung
transplant
highest
incid
invas
aspergillosi
among
solid
organ
transplant
recipi
common
invas
fungal
infect
lung
transplant
aspergillu
ubiquit
environ
acquir
inhal
three
main
describ
present
invas
pulmonari
diseas
tracheobronchi
aspergillosi
dissemin
diseas
associ
vari
degre
increas
mortal
implic
mold
includ
fusarium
scedosporium
mucormycosi
infect
difficult
treat
associ
poor
clinic
outcom
candida
spp
anoth
common
pathogen
lung
transplant
set
oral
candidiasi
common
manifest
infect
howev
candida
infect
also
manifest
candidemia
empyema
surgic
wound
infect
dissemin
diseas
seriou
candida
infect
associ
increas
mortal
though
rate
declin
time
fungal
infect
patient
popul
includ
opportunist
infect
pneumocysti
jiroveci
cryptococcu
well
endem
fungi
histoplasma
capsulatum
coccidioid
immiti
blastomyc
dermatitidi
viral
infect
contribut
morbid
mortal
acut
infect
associ
increas
risk
reject
chronic
allograft
dysfunct
lymphoprolif
neoplast
diseas
extra
pulmonari
organ
damag
cytomegaloviru
cmv
signific
viral
infect
occur
solid
organ
transplant
recipi
second
common
infect
bacteri
pneumonia
cmv
infect
rang
latent
infect
asymptomat
viremia
cmv
diseas
manifest
clinic
symptom
endorgan
involv
sever
diseas
may
rang
mild
life
threaten
organ
damag
affect
organ
includ
lung
pancrea
intestin
retina
kidney
liver
brain
cmv
diseas
associ
increas
mortal
notabl
dna
virus
herpesvirida
famili
includ
epsteinbarr
viru
ebv
associ
increas
risk
ptld
malign
herp
simplex
viru
hsv
varicellazost
viru
vzv
human
herpesviru
communityacquir
respiratori
virus
includ
influenza
major
sourc
respiratori
symptom
morbid
lung
transplant
infect
may
also
associ
develop
chronic
allograft
dysfunct
current
median
surviv
adult
lung
transplant
recipi
year
bilater
lung
recipi
appear
better
median
surviv
compar
singlelung
recipi
versu
year
overal
lung
transplant
confer
clinic
meaning
statist
signific
improv
healthrel
qualiti
life
hrqol
greater
lung
transplant
recipi
report
activ
limit
care
lung
transplant
recipi
multidisciplinari
labor
intens
comprehens
includ
manag
immunosuppress
regimen
opportunist
infect
prophylaxi
prevent
manag
variou
comorbid
complic
typic
medic
regimen
consist
three
class
immunosuppress
drug
ie
calcineurin
inhibitor
cellcycl
inhibitor
corticosteroid
well
opportunist
infect
prophylaxi
pneumocysti
jiroveci
fungal
infect
cmv
earli
postop
period
hospit
discharg
recipi
close
monitor
outpati
set
typic
clinic
visit
includ
thorough
medic
reconcili
clinic
exam
pulmonari
function
test
chest
radiograph
laboratori
examin
role
surveil
bronchoscopi
transbronchi
biopsi
monitor
lung
allograft
remain
unclear
lung
transplant
improv
surviv
qualiti
life
patient
endstag
lung
diseas
associ
multitud
noninfecti
infecti
complic
lung
transplant
recipi
one
shortest
surviv
rate
among
solid
organ
recipi
due
uniqu
characterist
lung
allograft
includ
uniqu
blood
suppli
risk
ischemia
disrupt
nativ
lymphat
neural
suppli
transplant
surgeri
exposur
immunogen
entiti
via
ventil
among
noninfecti
complic
pgd
vte
reject
import
one
clad
affect
patient
long
term
remain
signific
clinic
concern
contributor
earli
mortal
lung
transplant
recipi
lung
transplant
recipi
also
increas
risk
varieti
malign
due
underli
diseas
comorbid
immunosuppress
statu
thu
requir
vigil
monitor
screen
cancer
infecti
complic
ie
bacteri
fungal
viral
also
import
contributor
morbid
mortal
bacteri
pneumonia
cmv
commonli
seen
patient
requir
multidisciplinari
intens
followup
aftercar
ongo
vigil
earli
recognit
treatment
open
frequent
commun
recipi
caregiv
healthcar
team
provid
